Aluminum hydroxide
Dibasic, Monobasic, Monohydrate, Phosphate (aluminum hydroxide) is a small molecule pharmaceutical. Aluminum hydroxide was first approved as Sodium phosphates in plastic container on 1983-05-10. It is used to treat duodenal ulcer, dyspepsia, gastroesophageal reflux, gastrointestinal hemorrhage, and heartburn amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acid gone antacid | C200263 | 2024-10-22 |
| advanced antacid mint | C200263 | 2023-11-07 |
| advanced antacid regular strength | C200263 | 2023-11-01 |
| advanced regular strength antacid | C200263 | 2023-11-01 |
| almacone | OTC monograph final | 2010-12-01 |
| almacone double strength | C200263 | 2023-11-02 |
| aluminum hydroxide | C200263 | 2024-04-16 |
| aluminum hydroxide and magnesium carbonate | C200263 | 2023-11-29 |
| aluminum hydroxide, magnesium hydroxide and simethicone | C200263 | 2024-10-17 |
| aluminum hydroxide, magnesium hydroxide and simethicone suspension aluminum hydroxide, magnesium hydroxide and simethicone suspension maximum strength | OTC monograph final | 2023-08-01 |
Show 85 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sodium Phosphate, Dibasic, Anhydrous / Sodium Phosphate, Monobasic, Monohydrate, Osmoprep, Salix Pharms | |||
| 7687075 | 2028-06-22 | DS, DP | |
HCPCS
No data
Clinical
Clinical Trials
385 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | 15 | 26 | 27 | 15 | — | 73 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 4 | 3 | 2 | 5 | — | 13 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 4 | 3 | 2 | 4 | — | 12 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 2 | — | 4 | 1 | 2 | 9 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 3 | 5 | 1 | — | 9 |
| Hepatitis b | D006509 | — | — | 3 | 2 | 1 | 1 | 1 | 7 |
| Uterine cervical dysplasia | D002578 | EFO_1000910 | N87 | — | — | 1 | 2 | 4 | 7 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | — | 1 | 1 | 4 | 6 |
| Persistent infection | D000088562 | — | — | — | — | 1 | 1 | 4 | 6 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | 1 | 3 | 5 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 28 | 5 | 1 | — | 1 | 33 |
| Healthy volunteers/patients | — | — | — | 17 | 11 | 2 | — | 1 | 27 |
| Virus diseases | D014777 | — | B34 | 10 | 7 | 2 | — | — | 17 |
| Infections | D007239 | EFO_0000544 | — | 7 | 9 | 3 | — | — | 17 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | 11 | 10 | 1 | — | — | 16 |
| Communicable diseases | D003141 | — | — | 5 | 5 | 2 | — | — | 10 |
| Conjunctivitis | D003231 | HP_0000509 | H10 | 2 | 1 | 5 | — | — | 8 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | 1 | 4 | 4 | — | — | 8 |
| Allergic rhinitis | D065631 | — | J30.9 | 1 | 3 | 5 | — | — | 8 |
| Rhinitis | D012220 | EFO_0008521 | J31 | 1 | 3 | 5 | — | — | 8 |
Show 38 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 32 | 7 | — | — | — | 34 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 12 | 2 | — | — | — | 12 |
| Hookworm infections | D006725 | EFO_0007314 | B76 | 10 | 1 | — | — | — | 11 |
| Ancylostomiasis | D000724 | EFO_0007145 | B76.0 | 10 | 1 | — | — | — | 11 |
| Respiratory tract infections | D012141 | — | J06.9 | 2 | 5 | — | — | — | 7 |
| Norovirus | D029322 | — | — | — | 6 | — | — | — | 6 |
| Rna virus infections | D012327 | — | — | 3 | 3 | — | — | — | 6 |
| Zika virus infection | D000071243 | — | A92.5 | 5 | 1 | — | — | — | 6 |
| Respiratory tract diseases | D012140 | — | — | 2 | 3 | — | — | — | 5 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | 4 | 1 | — | — | — | 4 |
Show 58 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dengue | D003715 | — | A90 | 7 | — | — | — | — | 7 |
| Hiv | D006678 | — | — | 3 | — | — | — | — | 3 |
| Respiratory syncytial viruses | D012136 | — | — | 3 | — | — | — | — | 3 |
| Hiv seronegativity | D018023 | — | — | 2 | — | — | — | — | 2 |
| Poisoning | D011041 | EFO_0008546 | T65.91 | 2 | — | — | — | — | 2 |
| Equine encephalomyelitis | D004683 | — | — | 2 | — | — | — | — | 2 |
| Venezuelan equine encephalomyelitis | D004685 | EFO_0007534 | A92.2 | 2 | — | — | — | — | 2 |
| Zika virus | D000071244 | — | — | 2 | — | — | — | — | 2 |
| Schistosomiasis mansoni | D012555 | EFO_1001420 | B65.1 | 2 | — | — | — | — | 2 |
| Enterovirus infections | D004769 | EFO_0007255 | B34.1 | 2 | — | — | — | — | 2 |
Show 51 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 2 | 2 |
| Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | — | — | 1 | 1 |
| Ulcer | D014456 | MPATH_579 | — | — | — | — | — | 1 | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | — | — | 1 | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Cerebral palsy | D002547 | — | G80 | — | — | — | — | 1 | 1 |
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | — | — | — | 1 | 1 |
| Immunity | D007109 | — | — | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aluminum hydroxide |
| INN | — |
| Description | Aluminium hydroxide, Al(OH)3, is found in nature as the mineral gibbsite (also known as hydrargillite) and its three much rarer polymorphs: bayerite, doyleite, and nordstrandite. Aluminium hydroxide is amphoteric, i.e., it has both basic and acidic properties. Closely related are aluminium oxide hydroxide, AlO(OH), and aluminium oxide or alumina (Al2O3), the latter of which is also amphoteric. These compounds together are the major components of the aluminium ore bauxite. Aluminium hydroxide also forms a gelatinous precipitate in water.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O[Al](O)O |
Identifiers
| PDB | — |
| CAS-ID | 21645-51-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200706 |
| ChEBI ID | 33130 |
| PubChem CID | 10176082 |
| DrugBank | DB06723 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Aluminum hydroxide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,973 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,661 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use